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Introduction: The blood-brain barrier (BBB) is damaged in tauopathies, including progressive supranuclear palsy
(PSP) and Alzheimer’s disease (AD), which is thought to contribute to pathogenesis later in the disease course. In
AD, BBB dysfunction has been associated with amyloid beta (Aß) pathology, but the role of tau in this process is
not well characterized. Since increased BBB permeability is found in tauopathies without Aß pathology, like PSP, we
suspected that tau accumulation alone could not only be sufficient, but even more important than Aß for BBB
damage.
Results: Longitudinal evaluation of brain tissue from the tetracycline-regulatable rTg4510 tau transgenic mouse
model showed progressive IgG, T cell and red blood cell infiltration. The Evans blue (EB) dye that is excluded from
the brain when the BBB is intact also permeated the brains of rTg4510 mice following peripheral administration,
indicative of a bonafide BBB defect, but this was only evident later in life. Thus, despite the marked brain atrophy
and inflammation that occurs earlier in this model, BBB integrity is maintained. Interestingly, BBB dysfunction
emerged at the same time that perivascular tau emerged around major hippocampal blood vessels. However, when
tau expression was suppressed using doxycycline, BBB integrity was preserved, suggesting that the BBB can be
stabilized in a tauopathic brain by reducing tau levels.
Conclusions: For the first time, these data demonstrate that tau alone can initiate breakdown of the BBB, but the
BBB is remarkably resilient, maintaining its integrity in the face of marked brain atrophy, neuroinflammation and
toxic tau accumulation. Moreover, the BBB can recover integrity when tau levels are reduced. Thus, late stage
interventions targeting tau may slow the vascular contributions to cognitive impairment and dementia that occur
in tauopathies.
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The blood-brain barrier (BBB) is a physical barrier of
endothelial cells, supported by astrocytes, that selectively
limits the passage of peripheral blood components and
pathogens into the brain, while allowing the passage of
essential nutrients [1,2]. In aging, there is a decline in
the stability of the BBB leading to increased permeability
[3]. This disruption of BBB integrity is exacerbated in
Alzheimer’s disease (AD) [4-6], allowing peripheral* Correspondence: cdickey@health.usf.edu
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unless otherwise stated.immune cells access to the brain and perhaps exacer-
bating pathology by promoting detrimental neuroin-
flammation [7-10]. Most evidence suggests that this
increase in BBB damage is driven by accumulation of
amyloid-beta (Aß), particularly along the vasculature
[11-13]. However, the microtubule associated protein
tau has been shown to accumulate as puncta in peri-
vascular spaces in sporadic AD with cerebral amyloid
angiopathy (CAA) [14]. BBB damage is also observed
in tauopathies that lack Aß over-production [15-17],
suggesting a role for tau in BBB damage [18-21], although
this has yet to be proven.
We turned to the well-characterized tetracycline indu-
cible rTg4510 mouse model to address the gaps in our
knowledge about the role of tau in BBB damage. Theseis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tau tangle formation, neuroinflammation, neuronal loss
and cognitive deficits [22-24]. Overall tau accumulation is
detectable by 1 month of age, while insoluble tau, neuro-
toxicity, and atrophy, appear as early as 2.5 months of age
[22]. These pathologies progressively worsen and by
8.5 months of age, roughly 80% of neurons in the CA1
and dentate gyrus are lost [22,24-27]. Importantly, tau
expression can be suppressed by doxycycline (DOX)
administration in this model, a feature that can be
exploited to determine whether pathophysiological con-
sequences of tau expression can be halted. For example,
tau suppression was previously found to rescue memory
deficits and neuronal loss in this model, without affect-
ing the accumulation of neurofibrillary tangles [23].
Thus, we used this model to determine if and when
BBB integrity might be compromised, and whether this
was caused by tau accumulation alone, by brain volume
loss, or by some other pathology yet to be described. We
also exploited the DOX-regulation of this model to de-
termine if BBB damage was permanent, and whether
specific features of the model were most closely linked
to BBB dysfunction. We found that tau accumulation
does eventually lead to BBB disruption, but there is an
extremely high threshold of neuronal loss that the BBB
can withstand before losing integrity. In fact, onset of
BBB disruption was concomitant with the appearance of
perivascular tau, suggesting a relationship between these
two pathologies. BBB function was largely restored when
tau was suppressed, even well after onset of BBB dys-
function. These data suggest that tau accumulation can
disrupt BBB integrity and that BBB dysfunction coincides
with the appearance of perivascular tau. These findings
are important considerations for drug discovery efforts
based on this model because they suggest that the vascula-
ture can recover when tau levels are reduced, suggesting
that late stage interventions targeting tau may be useful
for slowing the vascular contributions to cognitive impair-
ment and dementia that occur in tauopathies.
Materials and methods
Study approval
All applicable international, national, and/or institutional
guidelines for the care and use of animals were followed.
All animal handling and procedures were carried out
in accordance with the University of South Florida’s
Institutional Animal Care and Use Committee (IACUC)
in accordance with the Association for Assessment and
Accreditation of Laboratory Animal Care International
(AALAC) regulations.
Mouse colony and tissue processing
The rTg4510 colony was bred and maintained as previously
described [22,23]. Mice were harvested at 1-, 3-, 6-, 9-, and12-months old (N = 5-8 per genotype). At sacrifice, mice
were perfused with 0.9% saline solution; brains were rapidly
removed and fixed with 4% paraformaldehyde overnight.
Following sucrose gradients up to 30%, tissue was sectioned
using a sliding microtome at a thickness of 25 μm.
Doxycycline treatment procedure
In the DOX treated groups, 10.5- to 11-month old
rTg4510 (N = 7) and wild-type (N = 7) mice were treated
for ~5 weeks with DOX and harvested at 12-months
old. When DOX treatment was started, mice were given
1.5 g/L DOX (Sigma Cat# 9891, St. Louis, MO;) in 4%
sucrose water for 48 hours. After two days, DOX water
was replaced by tap water and mice were fed a DOX diet
containing 0.2 g/kg DOX (Harlan Cat# TD.00502, In-
dianapolis, IN) until sacrifice.
Intracardiac injection of Evans blue (EB)
Intracardiac injection of EB (Sigma) was performed on
6- (N = 7), 9- (N = 8), 12- (N = 8), and 12-month old
DOX-treated (N = 7) rTg4510 and wild-type littermates
as previously described [28], with slight modification.
Mice were anesthetized by inhalation of precisely 2% iso-
flurane, to prevent variance of BBB opening due to iso-
flurane inhalation [29]. While in dorsal recumbency, hair
was removed from the injection site, the site was steril-
ized, and a percutaneous stick was made through the rib
cage between the 4th and 5th intercostal space from the
mouse’s left side. 20 mg/kg EB in sterile PBS was
injected into the left ventricle at a rate of approximately
200 μL/min forty minutes before sacrifice. Tissue was
harvested as describe above, including transcardiac per-
fusion to remove all blood from blood vessels.
Immunohistochemistry and immunofluorescence
Tissue was stained free floating as previously described
[30] with minor modifications using antibodies directed
against tau (H-150) (Santa Cruz, Dallas, Tx; 1:5000), heat
shock protein 27 kDa (Hsp27; c-20) (Santa Cruz; 1:5000),
Glial fibrillary acidic protein (GFAP; DAKO, Carpinteria,
CA; 1:3000), CD3+ (AbD serotec, Raleigh, NC; 1:30,000),
and CD4+ (AbD serotec; 1:30,000) with swine anti-goat
IgG BIOT (1:200), goat anti-rabbit IgG BIOT (1:10,000),
goat anti-mouse IgG BIOT (1:3000) and goat anti-rat IgG
BIOT (1:1000) secondary antibodies (Southern Biotech,
Birmingham, AL). Blood vessels were stained using
DyLight 488 labeled Lycopersicon Esculetum (Tomato)
Lectin (Vector Laboratories; Burlingame CA; 1:200). Fluo-
rescently stained tissues were stained free-floating as pre-
viously described [31]. Briefly, following permeabilization,
tissue was incubated with tau (H-150; 1:1000) and/or
Hsp27 (1:100) primary antibody overnight. Following
PBS washes, tissue was incubated with Alexa Fluor 488
donkey anti-goat IgG (Invitrogen, Grand Island, NY;
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(Invitrogen; 1:1000) secondary antibody for 2 hours,
followed by an overnight incubation with Tomato Lec-
tin 488 (1:500). Brightfield tissue was mounted, dehy-
drated, and coverslipped using DPX (VWR, Atlanta,
GA). Fluorescently stained tissue was mounted and
then coverslipped using ProLong Gold Antifade Reagent
(Invitrogen). Hematoxylin (Sigma) and eosin (Sigma)
(H&E) staining was performed on mounted tissue as
previously described [32] to view red blood cells (RBCs).
Following nuclear and cytoplasmic staining, tissue was
rapidly dehydrated in ethanol gradients, cleared in xylenes,
and coverslipped using DPX.
Tissue imaging and quantification
Stained tissue was imaged using a Mirax slide scanner.
IgG, tau (H-150), Hsp27, and GFAP were quantified in
the cortex and hippocampus by segmentation of positive
areas using NearCYTE software. As previously reported,
this software allows for the segmentation of positive
staining based on hue, saturation, and color intensity
compared to that of the background in very specific re-
gions of the tissue [33,34]. Consistent color settings were
used to analyze each piece of tissue, which was selected
for regions of interest based on a mouse brain atlas,
across each stain. CD3+ and CD4+ T cells along with
H&E positive red blood cells were manually counted by
a blinded investigator throughout each section.
For Lectin/tau staining images, z-stack images were
taken each 1 μm through the tissue using Leica TCS SP2
Confocal Microscope equipped with a 63x/ 1.4-0.60
PLAN APO Oil objective using Argon and Red HeNe la-
sers and I3 and N2.1 filters respectively. EB and Hsp27/
tau stain was imaged with an AxioCamMR3 camera on
a Zeiss AxioImage.Z1 using a 10×/0.25 dry Zeiss EC
Plan-Neofluar 10×/0.30 M27 objective. Positive signal
was excited using an EXFO X-Cite fluorescence illumin-
ator with 43HE: Cy3 filter (excitation 550/emission 605)
at a set exposure time of 750 ms for all tissue. Analysis
of EB images was performed using ImageJ software
(National Institutes of Health). Images were converted
to 8-bit and a threshold of 100-255 was applied. Particle
analysis was performed on areas between 0 and infinity
pixels2 and a circularity of 0.50-1.00, which allowed for
the analysis of all positive EB staining.
Image analysis and statistics
Six to eight sections per mouse were averaged together
as a single representative value for a brain region. Statis-
tical analysis was performed either using a 1-way or 2-
way analysis of variance (ANOVA) (Age and Genotype)
or (Age and Treatment) as appropriate. Values com-
pared between genotypes of a single age group were
analyzed by t-test. Values were considered significantwhen p <0.05. Graphs were generated using GraphPad
Prism 5.0.
Results
IgG extravasation in aged rTg4510 mice
The first indication that there could be BBB damage in
the rTg4510 mouse model was the presence of intense
background staining when using anti-mouse IgG sec-
ondary antibodies on aged tissue, similar to what has
previously been shown following AAV delivery of P301L
tau in wild-type mice [19,20]. This anti-IgG reactivity
was only observed in aged rTg4510 and not in age-
matched wild-type littermates or younger rTg4510 mice.
To investigate the progression and severity of the IgG
infiltration, a more thorough examination of IgG immu-
noreactivity was then performed on rTg4510 and wild-
type mice at 1-, 3-, 6-, 9-, and 12-months old. We found
that rTg4510 mice displayed progressively higher visible
levels of anti-mouse IgG immunoreactivity than age-
matched wild-type littermate (Figure 1a). The most vis-
ibly apparent regions affected by IgG accumulation were
the hippocampus, stemming from the fimbria of the
hippocampus, and the frontal cortex, most notably along
the edges of the tissue. Both the hippocampus and
frontal cortex have been characterized to have extensive
tau accumulation and severe neuron loss in rTg4510
model [24]. In fact, the hippocampus has been shown in
wild-type rodents to be susceptible to BBB impairment
[35,36], so this natural predisposition combined with the
intense pathology which is found throughout the hippo-
campus made this region particularly interesting. Anti-
mouse IgG quantification in the hippocampus revealed a
significant increase in 12-month old rTg4510 mice
(Figure 1b) compared to age-matched wild-type mice.
This same phenomenon was mirrored in previous studies
using hippocampal tissue of AD cases [5]. Upon closer
visual examination of the hippocampus in rTg4510 mice,
the highest accumulation of IgG was found in the CA3
(Figure 1c), however the dentate gyrus and the CA1 re-
gion were also noticeably darker than the wild-type lit-
termates. Although a similar pattern of staining were
seen in the hippocampus of the wild-type mice, the
overall staining was much lighter than that found in the
rTg4510 model. Since regions adjacent to periventricu-
lar areas are most prone to BBB permeability, it was not
surprising the CA3 region had the most IgG immunore-
activity [37]. In the frontal cortex, another region that
has significant tau accumulation and atrophy [38], IgG
immunoreactivity was also significantly increased in
12-month old rTg4510 mice compared to wild-type
littermates (Figure 1d and e). This immunoreactivity
was most marked on the edge of the tissue with a gra-
dient to lighter IgG reactivity radiating laterally in-
ward. Based on these findings, we speculated aging,
Figure 1 IgG accumulates with age in the rTg4510 mouse model. a Goat anti-mouse IgG staining on tissue from 1-, 3-, 9-, and 12-month old
rTg4510 and wild-type (WT) mice. Arrows indicate areas of most intense IgG accumulation in the frontal cortex and hippocampus. Scale bar represents
2000 μm. Quantification of the relative area ratio of IgG accumulation in the b hippocampus (± SEM). ** p <0.01, ***p< 0.001. 5× magnification of the
c hippocampus of 3-, 9-, and 12-month old rTg4510 and wild-type mice showing progressive accumulation of IgG in the hippocampus with age. Arrow
indicates CA3 area has more IgG accumulation. Scale bar represents 200 μm. Quantification of the relative area ratio of IgG accumulation in the d frontal
cortex (± SEM) of rTg4510 compared to wild-type mice with age. ***p < 0.001. 5x magnification of the e frontal cortex of 3-, 9-, and 12-month old
rTg4510 and wild-type mice showing progressive accumulation of IgG in the cortex with age. Arrow highlights the most accumulation of IgG is on the
surface of the cortex. Scale bar represents 200 μm.
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to BBB disruption.
Extravasation of immunoglobulin and EB in 12-month old
rTg4510 mice
To more thoroughly investigate BBB permeability in
these mice, three cohorts of rTg4510 mice and wild-type
littermates aged 6-, 9-, and 12-months old were intracar-
dially injected with EB, a dye that is typically occluded
from the brain except when the BBB is damaged. EB isFigure 2 Evans blue (EB) extravasation reveals blood-brain barrier dy
images of whole brains immediately following perfusion displayed gross a
mice. Scale bar represents 200 μm. Representative 20x images of b EB fluo
entorhinal cortex (ECTX), striatum (STR), and hippocampal commissure (HC
mice. Scale bar represents 50 μm. Representative whole brain image staine
mice showing map of locations used for EB fluorescent imaging in b. Scale
d hippocampus (± SEM) of 6-, 9-, and 12-month old rTg4510 and wild-type
frontal cortex (± SEM) e of 6-, 9-, and 12-month old rTg4510 and wild-typecommonly used for BBB studies and emits fluorescence
when bound to albumin in the blood [39-41]. Mice were
perfused to remove all blood from the brain. Thus any
fluorescent signal in the brain would indicate EB bound
to albumin in the parenchyma and not the surrounding
vasculature, indicative of BBB breakdown. Whole brains
from mice that received intracardiac EB injections were
imaged following sacrifice (Figure 2a). Blue staining was
visible in each of the 12-month old rTg4510 tau mice
predominantly in the cortical layers superior to thesfunction in rTg4510 mice by 12 months of age. Representative
EB extravasation (black arrowhead) in 9- and 12-month old rTg4510
rescence in the CA1, CA3, dentate gyrus (DG), frontal cortex (CTX),
) of 12-month old wild-type and 6-, 9-, and 12-month old rTg4510
d with c anti-mouse IgG from 12-month oldwild-type and rTg4510
bar represents 2000 um. Quantification of EB fluorescence in the
mice. ***p <0.001, ** p <0.01. Quantification of EB fluorescence in the
mice. *** p <0.001, ** p <0.05.
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IgG on the surface of the cortex (Figure 1e). This blue
staining was not visible in 6-month old rTg4510 mice or
12-month old wild-type littermates, but was seen to a
lesser extent in some 9-month old rTg4510 mice.
Brain tissue was fixed, sectioned, and mounted for
brain region specific analysis of EB. EB fluorescence was
found to be highest in 12-month old rTg4510 mice,
compared to younger rTg4510 mice or age-matched
wild-type mice (Figure 2b). Regions with high EB expres-
sion corresponded to those with greatest anti-mouse
IgG immunoreactivity (Figure 2c), the highest being the
hippocampus and the cortex, followed by the entorhinal
cortex and hippocampal commissure. This again shows
that periventricular regions are most susceptible to BBB
dysfunction [37], and that this is severely exacerbated in
the rTg4510 mouse model. Thus, we analyzed the extrava-
sation of EB in the hippocampus and frontal cortex, since
these areas showed prominent IgG infiltration. Significant
EB fluorescence was observed in the hippocampus
(Figure 2d) and frontal cortex (Figure 2e) of 12-month
old rTg4510 mice but not in 6-month old rTg4510
mice or any wild-type mice. Similar to IgG, extravasa-
tion of EB was greatest in the CA3 region of the hippo-
campus (Additional file 1: Figure S1), compared to the
CA1 and dentate gyrus, however both of these regions
still showed significant EB accumulation. 9-month old
rTg4510 mice showed high levels of EB fluorescence in
both the hippocampus and frontal cortex which were
significant by Student t-test, but not ANOVA. Thus
rTg4510 mice can develop a major BBB defect, but this
is only significant after 9 months of age, well after
robust brain atrophy and tau accumulation begins in
this model.
Increasing tau accumulation is accompanied by glial
activation
As previously reported [22,23,42], tau accumulation was
significantly increased in an age-dependent manner in the
hippocampus (Figure 3a) and frontal cortex (Figure 3b) of
rTg4510 mice. Tau accumulation throughout the brain ac-
companied by visible brain atrophy, including the hippo-
campus (Additional file 1: Figure S2), was progressively
increased in mice from 6 to 12 months of age (Figure 3c).
Tau staining in the hippocampus (Figure 3d) and frontal
cortex (Figure 3e) showed region-specific increases in tau
accumulation with age.
It is well-documented that tau accumulation in the
rTg4510 mouse model induces neuroinflammation, in-
cluding microgliosis and astrocytosis [24,30,32,43]. In
fact, there is a robust inflammatory response that begins
somewhere between 2 and 4 months of age in these
mice [43]. This inflammation is closely correlated with
neurodegeneration in this model and can be reversed byDOX-treatment [20,38,43]. Here we focused on astrocy-
tosis rather than microgliosis given the intimate role of
astrocytes with BBB stability [44]. We investigated the
levels and morphology of heat shock protein 27 kDa
(Hsp27) in 6-, 9-, and 12-month old rTg4510 and age-
matched wild-type mice. Hsp27 was selected because it
has been shown to increase with age [22], is highly
expressed in activated astrocytes [45], is found lining
blood vessels [46], is constitutively expressed in vascular
endothelial cells [47], and has been implicated in regula-
tion of the BBB through its role in actin stabilization
[48]. We found that Hsp27 levels in the hippocampus
(Figure 4a) and frontal cortex (Figure 4b) were signifi-
cantly increased in rTg4510 mice at 12 months of age.
This progressive increase was clearly visible throughout
entire brain sections (Figure 4c). Upon closer examin-
ation of the hippocampus (Figure 4d) and frontal cortex
(Figure 4e), Hsp27 immunoreactivity appeared adjacent
to blood vessels and with age these astrocytes appeared
more activated (Figure 4f ). The age-related increases in
Hsp27 were significantly exacerbated by tau overexpres-
sion (Figure 4a and b).
To confirm the accumulation of astrocytes as detected
by Hsp27 staining, we also stained tissue from 6-, 9-,
and 12-month old rTg4510 and wild-type mice for
GFAP, a more traditional marker of astrocytes [18,49,50].
Similar to the results from Hsp27, GFAP was significantly
elevated in the hippocampus (Figure 5a) and frontal cortex
(Figure 5b) of aged rTg4510 mice compared to wild-type
controls. Whole brain sections show that accumulation of
GFAP followed a similar pattern to that of tau in the
rTg4510 mice (Figure 5c). Closer examination of the
hippocampus (Figure 5d) showed that there was an age re-
lated increase in GFAP immunoreactivity that was exacer-
bated in the rTg4510 mice starting at 9 months of age,
significantly higher than wild-type mice. While the
rTg4510 cortex (Figure 5e) showed less of an age-
related increase in GFAP immunoreactivity, there was
still a clear elevation starting at 6 months of age that
progressively increased.
Invasion of red blood cells and T cell lymphocytes is
evident in aged rTg4510 mice
Blood component infiltration into the brains of aged
rTg4510 mice suggested impaired BBB integrity. There-
fore, we sought to determine if whole peripheral blood
cells could also enter the parenchyma with age. Brain sec-
tions from 6-, 9-, and 12-month old rTg4510 mice were
stained with hematoxylin and eosin (H&E) to visualize red
blood cells (RBCs; erythrocytes) that remained in the brain
parenchyma following perfusion [51]. RBCs, which are
highly eosinophilic, stain bright red with circular morph-
ology void of blue nuclear staining by H&E staining.
These RBCs were manually counted throughout at least 6
Figure 3 Tau (H-150) accumulation in aging rTg4510 mice. Tissue from aging rTg4510 mice were stained with total tau (H-150) and
quantified for total tau (H-150) in the a hippocampus (± SEM) and b frontal cortex (± SEM) in rTg4510 mice. *** p <0.001. Representative images
of a whole section stained with c total (H-150) tau from a 6-, 9-, and 12-month old rTg4510 mouse. Scale bar represents 2000 μm. Representative
images from corresponding d hippocampus and e frontal cortex are shown. Scale bars represent 200 μm; hippocampus inset scale bar
represents 50 μm.
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old cohorts. Significantly more RBCs were found in the
rTg4510 parenchyma at 12 months of age (Figure 6a, b).RBCs appeared to infiltrate the tissue near ventricles,
the outer edges of the cortex, and along vasculature,
particularly in the hippocampus.
Figure 4 Hsp27 abundance increases with age in rTg4510 mouse brain. Hsp27 staining was quantified in the a hippocampus (± SEM) and
b frontal cortex (± SEM) of 6-, 9-, and 12-month old rTg4510 and wild-type mice. ***p <0.001. Representative images of the c whole brain, d hippocampus
(from CA1 region), and e frontal cortex are shown. Scale bars represent 2000 μm, 50 μm, and 200 μm respectively. High magnification images of f blood
vessels in the hippocampus from 6- and 12-month old rTg4510 mice. Scale bar represents 20 μm.
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Figure 5 GFAP positive astrocytes accumulate with age in rTg4510 mice. Area ratio positive for GFAP immunoreactivity was quantified in
the a hippocampus (± SEM) (*p = 0.01696; ***p <0.001) and b frontal cortex (± SEM) (6-month *p = 0.020102, 9 month *p = 0.04813, ***p <0.001)
of wild-type and rTg4510 mice at 6, 9 and 12 months of age; c representative whole brain images are shown. Scale bar represents 2000 μm.
Representative images of d hippocampus (± SEM) and e cortex (± SEM) of GFAP immunostained tissue from 6-, 9- and 12-month old wild-type
and rTg4510 mice. Scale bar represents 100 μm; inset scale represents 20 μm.
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mune cells into the brain, staining for CD3+ T cells was
performed. CD3+ T cells significantly infiltrated the
brain of 12-month old rTg4510 mice (Figure 6c), espe-
cially near the longitudinal hippocampal blood vessels
(internal transverse hippocampal artery and/or vein;
Figure 6d) and periventricular to the lateral ventricles
(Figure 6e), but were rarely observed in age-matchedFigure 6 Erythrocytes and leukocytes infiltrate the brain of aged rTg45
mice were stained with hematoxylin and eosin (H&E) and a red blood cells (R
A 40x representative image of b H&E staining from 12-month old rTg4510 an
Arrowheads indicate positive RBCs. T cell lymphocytes were stained with c CD
and age-matched wild-type mouse tissue. *** p <0.001. CD3+ T cells were fou
around the e ventricles. Arrowheads indicate positive CD3+ T cells. However,
of age-matched wild-type littermates. Scale bar represents 50 μm in the hippo
lymphocytes stained for g CD4+ were counted (± SEM) in 6-, 9-, and 12-mont
found in the h hippocampus and in and around the i ventricles of 12-month o
staining in the tissue or ventricles of age-matched wild-type littermates. Arrow
hippocampus and ventricle images; inset scale bar represents 20 μm.wild-type mice (Figure 6f ). CD4+ T cells were also found
to significantly infiltrate the brains of 12-month old
rTg4510 (Figure 6g) mice compared to their younger
counterparts and to age-matched wild-type mice. The
infiltration of these CD4+ T cells were found in similar
regions as CD3+ T cells, along the longitudinal hippo-
campal blood vessels (Figure 6h) and near periventricu-
lar regions (Figure 6i and j). Taken together, these data10 mice. Sections from 6-, 9-, and 12-month old rTg4510 and wild-type
BCs) (± SEM) were manually counted throughout the brain. *** p <0.001.
d wild-type mice is shown. Scale bar represents 50 μm; 20 μm inset.
3+ antibody and counted (± SEM) in 6-, 9-, and 12-month old rTg4510
nd in 12-month old rTg4510 mice in the d hippocampus and in and
there was very little positive staining was found in the f tissue or ventricles
campus and ventricle images; inset scale bar represents 20 μm. T cell
h old rTg4510 and wild-type mouse tissue. *** p <0.001. CD4+ T cells were
ld rTg4510 backspace. Similar to CD3+ T cells, there was little j CD4+-positive
heads indicate CD4+ positive T cells. Scale bar represents 50 μm in the
Figure 7 (See legend on next page.)
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Figure 7 Tau suppression by DOX slows BBB defect in 12-month old rTg4510 mice. IgG levels in the (a and b) hippocampus (± SEM) and
(c and d) frontal cortex (± SEM) of 12-month old DOX-treated mice compared to 9- and 12-month old wild-type and rTg4510 mice; Representative
images are shown. *** p <0.001, ** p <0.01. Scale bar represents 200 μm. Images of e whole brains immediately following perfusion to observe Evans
blue (EB) (black arrowhead) in 12 month DOX-treated mice compared to 9 and 12 month old rTg4510 relative to matching wild-type mice. Scale bar
represents 200 μm. Positive EB expression was measured in the (f and g) hippocampus (± SEM) and (h and i) frontal cortex (± SEM) of 12 month old
DOX-treated mice compared to 9- and 12-month old rTg4510 and age-matched wild-type mice; representative images of 9-month old, 12-month old,
and DOX-treated 12-month old mice are shown. * p <0.05**, p <0.01. Scale bar represents 50 μm. Relative j hippocampal brain volume (± SEM) in
9- and 12-month old rTg4510 mice compared to 12-month old rTg4510 mice treated with DOX. *** p <0.001.
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mice is sufficient to not only allow blood components
into the brain, but also whole blood cells.
Tau suppression by doxycycline restores BBB integrity
We next sought to test the resiliency of the BBB to dam-
age caused by tau accumulation. We took advantage of
the ability to suppress tau expression in the rTg4510
model using DOX feed. DOX was fed to 10.5- and 11-
month old rTg4510 and wild-type mice for ~5 weeks. At
12 months of age, mice were injected with EB forty mi-
nutes before perfusion and tissue was collected following
this in an identical manner to the cohorts described
above. Immunostaining revealed that the levels of IgG
were lower in 12-month old rTg4510 mice that received
DOX treatment compared to the untreated group. In
fact, the IgG immunoreactivity in the hippocampus
(Figure 7a and b) and frontal cortex (Figure 7c and d) of
mice treated with DOX beginning at ~11 months was
indistinguishable from 9-month old rTg4510 mice, sug-
gesting that tau suppression by DOX could slow and
possibly reverse the BBB dysfunction in these mice.
Superficial examination of EB staining also suggested
that DOX-treated 12-month old rTg4510 mice resem-
bled 9-month old rTg4510 mice with regard to EB ex-
travasation (Figure 7e). Histochemical analysis of the
area ratio of EB extravasation in these mice showed that
the hippocampi of 12-month old DOX-treated rTg4510
mice were quantitatively indistinguishable from either 9-
month old or 12-month old untreated rTg4510 (Figure 7f
and g), and the frontal cortex had significantly lower
levels of EB compared to 12-month old untreated
rTg4510 mice (Figure 7h and i). Similar trends were ob-
served for EB particle count, total area positive and aver-
age particle size (Additional file 1: Figure S3) Taken
together, this suggests that BBB integrity was maintained
and in part restored following tau suppression by DOX.
As expected, hippocampal atrophy was also significantly
slowed by DOX treatment, as measured by traces used
for segmentation from NearCYTE software (Figure 7j).
However, 12-month old DOX-treated rTg4510 mice still
had significantly lower hippocampal volume than 9-
month old untreated rTg4510 mice. Altogether, thesedata suggest that tau suppression can slow and possibly
even rescue the progression of BBB dysfunction in this
model of tauopathy.
Tau suppression slows and possibly reverses BBB
dysfunction in aged rTg4510 mice
As expected, total tau levels in DOX-treated mice were
significantly decreased in the hippocampus (Figure 8a
and b) and frontal cortex (Figure 8c and d) compared to
untreated rTg4510 mice. As depicted by the representa-
tive images in the hippocampus (Figure 8b) and frontal
cortex (Figure 8d), there was a noticeable reduction of
the dispersed tau-positive staining in the 12-month old
DOX-treated and 9-month old rTg4510 mice compared
to 12-month old untreated rTg4510 mice. In fact, the
DOX treated mice were statistically indistinguishable
from 9-month old untreated rTg4510 mice. This reduc-
tion in dispersed tau staining may be due to a decrease
in more soluble tau species which are lowered by DOX,
since previous studies showed that insoluble neurofibril-
lary tangles are not cleared by tau suppression [23].
Hsp27 accumulation was also significantly reduced by
tau suppression in both the hippocampus (Figure 8e and f)
and frontal cortex (Figure 8g and h), but was still sig-
nificantly higher than 9-month old untreated rTg4510
mice in the hippocampus (Figure 8e). In addition to
slowing the accumulation of the levels of Hsp27, the
morphology of cells expressing Hsp27 appears to be
slightly altered in both the hippocampus (Figure 8f )
and frontal cortex (Figure 8h), suggesting that distinct
activation states of astrocytes may also contribute to
BBB disruption.
Confirmation of the reduction of activated astrocytes
in DOX-treated rTg4510 mice was verified by GFAP
staining, which was recently shown to be rescued by
DOX in a separate study [43]. Consistent with Hsp27
staining, GFAP immunoreactivity was significantly lower
in the hippocampi of 12-month old DOX-treated
rTg4510 mice compared to their untreated counterparts
(Figure 9a and b), but still significantly higher than
9-month old untreated rTg4510 mice. In the frontal cortex,
GFAP immunoreactivity in 12-month old DOX-treated
mice was significantly lower than 12-month old untreated
Figure 8 Effects of tau suppression on tau and Hsp27 levels. Quantification of relative tau (H-150) levels in the (a and b) hippocampus
(± SEM) and (c and d) frontal cortex (± SEM) of DOX-treated 12-month old rTg4510 mice compared to 9- and 12-month old untreated rTg4510
mice; representative images are shown. Scale bar in cortical images represents 100 μm. *** p <0.001 Scale bar in hippocampal images represents
200 μm; inset scale bar represents 50 μm. Relative levels of Hsp27 in the (e and f) hippocampus (± SEM) and (g and h) frontal cortex (± SEM)
from 12-month old DOX-treated mice compared to 9- and 12-month old mice, relative to wild-type controls; representative images are shown.
Scale bar represents 20 μm. ** p <0.01, *** p <0.001.
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mice (Figure 9c and d).
T cell lymphocyte and RBC infiltration were also reversed
by tau suppression. The RBC counts from 12-month
old DOX-treated rTg4510 mice was significantly lower
than 12-month old untreated rTg4510 mice and wereindistinguishable from 9-month old untreated rTg4510
mice (Figure 9e). We also found that CD3+ (Figure 9f )
and CD4+ (Figure 9g) T cells were significantly lower
in the DOX-treated rTg4510 mice compared to un-
treated mice. Unlike CD3+ T cells, CD4+ T cells, while
reduced, were still significantly higher in 12-month old
Figure 9 (See legend on next page.)
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Figure 9 Effects of tau suppression on GFAP levels, RBCs and infiltration of T cell lymphocytes. Relative levels of GFAP positive astrocytes
in the (a and b) hippocampus and (c and d) frontal cortex of 9-, 12-, and 12-month old + DOX treated rTg4510 and wild-type mice; representative
images are shown. Scale bars represent 50 μm. * p <0.05, ** p <0.01, *** p <0.001. Number of e RBCs (± SEM) counted from H&E staining of 12-month
old DOX-treated and 9-and 12-month old untreated rTg4510 mice relative to the levels of their wild-type littermates. * p <0.05, *** p <0.001. Number
of f CD3+ (± SEM) and g CD4+ (± SEM) T cell lymphocytes in 9-, 12- and DOX-treated 12-month old rTg4510 mice compared wild-type controls
* p <0.05, ** p <0.01, *** p <0.001.
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rTg4510 mice.
Appearance of perivascular tau in 12-month old rTg4510
mice
Since the hippocampi of the rTg4510 model develop the
most robust and aggressive tau pathology, we examined
this area for any apparent differences in the morphology
of tau staining. Through this process, we discovered tau
immunoreactivity in and around the longitudinal blood
vessels of the hippocampus (Figure 10a; additional ex-
amples are included in Additional file 1: Figure S4a)
[52,53]. Quantification of this perivascular tau revealed
that it was significantly more abundant in 12-month old
rTg4510 mice than in 9-month old rTg4510 mice or
12-month old DOX-treated rTg4510 mice (Figure 10b).
Tau was not localized to this region in 12-month old
wild-type mice (Figure 10c) or in 6-month old rTg4510
mice (Figure 10d). It only emerged in rTg4510 mice
9 months of age or older (Figure 10e). We found that
the accumulation of tau in and around these blood ves-
sels was significant by 12-months of age (Figure 10f ),
but was markedly reduced in DOX-treated rTg4510
mice (Figure 10g). Lectin and tau co-staining (Figure 11)
revealed that tau was found closely lining the endothelial
cells of the blood vessels in the hippocampus in 12-month
old rTg4510 mice. This was not found in age-matched
WT mice and appeared less robust in 12-month old
DOX-treated mice. These findings suggest that tau along
these vessels is not within endothelial cells based on the
lack of co-localization of tau with lectin staining. We then
performed co-localization studies of Hsp27, tau and EB to
better define the location of this perivascular tau. Tau was
found co-localized with both EB and Hsp27, suggesting
that tau and EB were within Hsp27 positive cells along the
vasculature (Additional file 1: Figure S4b). Since tau did
not appear to co-localize with endothelial cells, and since
tau has not been found in neuroglia up to 13 months in
the rTg4510 mice by electron microscopy [54], we can
conclude that the perivascular tau is likely either within
neuronal processes that could contain Hsp27 and EB, or
it could be extracellular as both EB and Hsp27 are
found outside of cells as well [55,56]. Regardless of the
localization of this perivascular tau, its emergence coin-
cides much more closely with BBB dysfunction than
other pathologies in this model, such as neuronal lossand gliosis. Thus, these findings suggest an important
relationship between this perivascular tau pathology
and BBB integrity.
Discussion
This study is the first to demonstrate that tau derived
from neurons can be sufficient to initiate BBB impair-
ment. This dysfunction was found to be concomitant
with perivascular tau accumulation, subsequent to the
onset of other pathologies found in this mouse model.
In fact, the BBB is remarkably stable in the face of robust
tau accumulation, neuroinflammation, and neurodegener-
ation. This is based on our data showing that BBB dys-
function only manifested once vascular tau emerged at
9 months, well after neuronal loss and total tau accu-
mulation begin at 2.5 months and gliosis at 4 months
(Figure 12) [24,43]. In fact, BBB function in the rTg4510
mice was found to deteriorate at a similar time point as
the emergence of perivascular tau along the hippocam-
pal vessels (Figure 10f, g and h). The accumulation of
tau in the forebrain and hippocampus [24] is the nexus
which leads to BBB dysfunction in the rTg4510 model,
either directly or indirectly.
Tau-induced neuronal loss and inflammation are ap-
parent much earlier in the rTg4510 model than BBB
dysfunction. But while inflammation in particular is a
known regulator of BBB stability [57], gliosis emerges
at nearly the same time and place as tau aggregates
begin to appear in the rTg4510 model, both of which
occur at a much younger age relative to the emergence
of BBB pathology. This suggests that there may be a
threshold that tau-induced inflammation and/or neuro-
degeneration must surpass to induce BBB permeability
at 9 months in this model. Alternatively, it could be a
distinct pathology that arises, such as the accumulation
of perivascular tau, or a combination of these factors.
Interestingly, BBB damage in this model appeared
greatest in areas such as CA3 and the surface of the
cortex, adjacent to the areas that have the most robust
neuronal loss and gliosis such as CA1 and frontal mid-
cortical layers. In fact, BBB damage was highest near
the ventricles and the meninges, the same areas that
show signs of BBB leakage in normal aging [37]. In this
way, the BBB damage in the rTg4510 brain is similar to
that in the normal aging brain with regard to location
of initial insult; however this pathology is greatly
Figure 10 (See legend on next page.)
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Figure 10 Tau accumulates along hippocampal blood vessels in 12-month old rT4510 mice. 20x magnification image of the
a hippocampus of a 12-month old rTg4510 mouse stained with tau (H-150) to show the region of perivascular tau accumulation. Scale
bar represents 100 μm. Relative levels of b tau (H-150) (± SEM) were measured in and around the longitudinal hippocampal blood
vessels in 9- and 12-month old and 12-month old rTg4510 mice treated with DOX. ***p <0.001. Representative images of tau (H-150)
stained tissue from a c 12-month wild-type mouse and rTg4510 mice at d 6, e 9, and f 12 months of age, and g 12-month old
rTg4510 mice DOX-treated mice are shown. Scale bars represent 50 μm.
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tau accumulation somehow interact with normal aging
pathologies to cause this BBB damage. While the pre-
cise mechanism contributing to BBB dysfunction in
these mice remains unknown, it is clear that the brain
is highly resistant to BBB damage in the face of major
pathological insults, and only results through a com-
plex pathogenic cascade much later in the rTg4510
brain.
Still, the specific mechanism by which tau causes BBB
dysfunction remains unclear. Perhaps tau aggregation
works in a way that is similar to vascular Aß, by decreas-
ing glucose transporters [58] stimulating reactive oxygen
species [59], and increasing inflammatory molecules
[59-61]. In fact, tau accumulation is associated with in-
creased inflammation leading to stimulation of TNF-α
and MCP-1, and both of these have been implicated in
BBB dysfunction [21,62]. Moreover, the tau accumulat-
ing along the vasculature in the rTg4510 mice could be
extracellular, perhaps suggesting some type of physical
damage to the endothelial cells. There is evidence that
tau transgenic models do produce extracellular tau
[63,64] and recent work suggests that tau can spread in
a prion-like manner in these same mouse models
[65-67], further suggesting the potential for a patho-
logical role of extracellular tau. Tau has also been shown
to accumulate into annular protofibrils, which may be
able to puncture membranes [68], suggesting perhaps
another way for tau to damage the BBB. It is also pos-
sible that tau is able to damage the BBB from within
cells. In human AD brain, it was recently demonstrated
that tau is not only found near the vasculature [14], but
tau oligomers specifically co-localized with endothelial
cells within the blood vessels, suggesting that tau was ei-
ther extracellular or within pericytes or endothelial cells
[69]. However our data would suggest that this is not
the case in the rTg4510 model, since tau did not strongly
co-localize with lectin staining. Another possibility is
that neuronal tau accumulation triggers astrocytosis,
causing these cells to detach from tight junctions. Also,
while likely not relevant to this model because there is
no pathological evidence of glial tau in the rTg4510
mice, astrocytic tau has been shown to compromise the
BBB by damaging endfeet [18]. Still another mechanism
is that tau within endothelial cells themselves canbecome aberrantly phosphorylated, leading to BBB dis-
ruption [54,70,71].
Interestingly, vascular tau is also found in AD cases
with CAA [72-74], but this has typically been hypothe-
sized to be downstream of Aß-triggered BBB dysfunction,
rather than a causal pathology. There is also evidence that
mouse models expressing both mutant amyloid precursor
protein or Presenilin 1 have some tau present along
the vasculature [13,75], but this was speculated to be a
consequence of Aß deposition rather than a patho-
physiological function of tau. Thus, while the prevailing
dogma in AD is that Aß triggers the BBB dysfunction, our
findings clearly show that tau alone is capable initiating
impaired BBB stability independent of Aß.
Perivascular tau is also present in progressive supra-
nuclear palsy (PSP) and corticobasal degeneration (CBD),
suggesting that AD is not the only tauopathy to show a
BBB defect [76,77]. In contrast to PSP and CBD, AD tau
tangles contain exon 10 (+) and exon 10 (-) tau species
while tangles from PSP and CBD are exclusively exon 10
(+). Both PSP and AD have neuritic plaques, but only AD
has neuropil threads. Moreover, tau pathology in the AD
brain originates in the entorhinal cortex and hippocam-
pus, eventually spreading throughout the forebrain, but in
PSP tau pathology is restricted to the basal ganglia, brain-
stem, substantia nigra, and subthalamic nucleus [78,79],
and in CBD it is restricted to the cerebral cortex [79].
Perhaps most distinct is that tau in PSP and CBD brain
accumulates within astrocytes [76], while AD brain
shows no signs of neuroglial tau pathology. Despite
these distinct pathologies, like AD, there is clear evi-
dence for BBB damage in PSP that has been associated
with decreased P-glycoprotein, a transporter found in
endothelial cells within the BBB [15,77]. Unlike AD
where the perivascular tau is thought to arise from neu-
rons, perivascular tau in PSP was attributed to tau de-
rived from tangle bearing thorn-shaped glial cells [80]
and perivascular tau in CBD is most closely associated
with astrocytic tau [81]. But, despite different origins,
perivascular tau accumulates in each of these diseases,
providing further support for a role of tau pathology in
BBB damage. Thus, the rTg4510 mice likely most accur-
ately model the BBB defect caused by tau in the AD
brain since the tau is neuronally derived and the loca-
tion of the pathology. However, since the accumulation
Figure 11 Perivascular tau is found along the blood vessels in 12-month old rTg4510 mice. 63x magnification images of tau
(H-150; red) and Lectin 488 (green) along the hippocampal blood vessels from 12-month old WT, rTg4510 and DOX-treated mice.
Scale bar represents 20 μm.
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sible that the rTg4510 mice, which also have perivascular
tau accumulation, could define the role of this particular
tau pathology in BBB function.Conclusion
In summary, we show that tau derived from neurons
causes a progressive BBB dysfunction that is most closely
correlated with the emergence of perivascular tau, rather
Figure 12 BBB breakdown correlates best with perivascular tau levels. Representative schematic depicting the timeline of
progressive pathologies found in rTg4510 mice including tau accumulation, neuronal loss, tau tangle deposition, inflammation,
appearance of perivascular tau, and initiation of increased BBB permeability. Tau accumulation begins at a very young age, before one
month, followed by regional neuronal loss. A few months after tau tangles start to deposit just after signs of inflammation are
noticeable. Neuron loss continues to get more severe with age and by 9 months vascular tau is detectable in the hippocampus,
concomitant with the start of increased BBB permeability.
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occurs much earlier in the pathogenic cascade of the
rTg4510 model. Importantly, reducing tau levels recovered
the BBB defect, demonstrating its remarkable resiliency,
even in the face of dramatic degeneration and inflamma-
tion. Thus, the threshold for BBB integrity is extremely
high in the mouse brain and as a result BBB damage ap-
pears to be the last chip to fall in the neurotoxic sequelae
of this model. Furthermore, this BBB defect in the
rTg4510 mouse model can now be used to more ad-
equately model the pharmacokinetic profile of promis-
ing pre-clinical therapies to treat tauopathies, since
BBB dysfunction is found in AD, traumatic brain injury
(TBI) and other tauopathies. Since peripheral infiltra-
tion of inflammatory components into the brain is
thought to contribute to the late stage sequelae in AD
and other tauopathies [82-85], our findings suggest
that even late stage interventions targeting tau could
help maintain BBB integrity and reduce the vascular
contributions to cognitive impairment and dementia
that occur in these diseases. Overall, this work demon-
strates that tau accumulation can damage the BBB to
the point that whole peripheral cells can now enter the
brain, perhaps initiating a secondary disease cascade
involving the peripheral immune system. But this process
is late in the disease process and can be stopped if tau
levels are reduced.Additional file
Additional file 1: Figure S1. Evans blue fluorescence in subregions of
the hippocampus. Quantification of EB fluorescence in the CA1, CA3, and
dentate gyrus regions of the hippocmapus from 12-month old rTg4510
and wild-type mice. ***p<0.001. Figure S2. Hippocampal atrophy with
aging in the rTg4510 mouse model. Quantification of relative hippocampal
volume at 6-, 9- and 12-months. *p<0.05, ***p<0.001. Figure S3. Additional
Evans blue (EB) measurements. Average count of independent EB positive
spots per a hippocampus and b frontal cortex. *p<0.05, **p<0.01. Total EB
positivity (pixels) in each c hippocampus and d frontal cortex. ***p<0.001.
Average size of independent EB positive areas per e hippocampus and
f frontal cortex. ***p<0.001. Figure S4. Perivascular tau is found along
the hippocampal blood vessels. a Total tau (H-150) reactivity in thehippocampus of 12–month old rTg4510 mice. Images taken at 20×
magnification. Scale bar represents 100 μm. b Representative images of
hippocampal blood vessels from 12-month old wild-type, rTg4510 and
rTg4510 + DOX stained for Hsp27, tau (v-20), and Evans blue. Images
taken at 60x magnification. Scale bar represents 50 μm.Abbreviations
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